718P A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment
T.B. Powles, Stéphane Oudard, Viktor Grünwald, E. Calvo, M. Dror Michaelson, Mauricio Burotto, Bohuslav Melichar, Richa Tyagi, F. Hilmi, Anil Gaur, Yulia Hirschberg, Daniel Yick Chin Heng
Topics & Concepts
MedicinePazopanibClinical endpointInternal medicineRenal cell carcinomaOncologyProgression-free survivalPhases of clinical researchTyrosine-kinase inhibitorToxicityChemotherapyUrologySurgerySunitinibClinical trialCancerRenal cell carcinoma treatmentCancer Genomics and DiagnosticsRenal Diseases and Glomerulopathies